Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer
Roberto Alva‐Ruiz(Mayo Clinic in Arizona), Mark J. Truty(Mayo Clinic in Arizona), Sean P. Cleary(University Health Network), Wen Wee(Roswell Park Comprehensive Cancer Center), Travis E. Grotz(Mayo Clinic in Arizona), Jennifer A. Yonkus(Mayo Clinic in Arizona), Rondell P. Graham(Mayo Clinic in Arizona), Christopher L. Hallemeier(Mayo Clinic in Arizona), David M. Nagorney(Mayo Clinic in Arizona), Rory L. Smoot(Pancreas Centre (Canada)), Amro M. Abdelrahman(Mayo Clinic in Arizona), T.R. Halfdanarson(Mayo Clinic in Arizona), Lindsey A. Gregory(Mayo Clinic in Arizona), Michael L. Kendrick, Amit Mahipal(Dana-Farber Cancer Institute), Lavanya Yohanathan(Beaumont Hospital, Royal Oak), Robert R. McWilliams(Mayo Clinic in Arizona)
Cited by 68
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Cholangiocarcinoma — evolving concepts and therapeutic strategies
|Nature Reviews Clinical Oncology|2017|1.7k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort
|Journal of Clinical Oncology|2016|859
Non–Small Cell Lung Cancer, Version 4.2024
|Journal of the National Comprehensive Cancer Network|2024|746